DEFA14A: Singular Genomics to be Acquired by Deerfield in $20 Per Share All-Cash Deal

Singular Genomics Systems, Inc. has entered into a definitive agreement to be acquired by an affiliate of Deerfield Management Company, L.P. for $20.00 per share in cash.

Summary

• Singular Genomics Systems, Inc. has agreed to be acquired by an affiliate of Deerfield Management Company, L.P. in an all-cash transaction.
• The purchase price is $20.00 per share.
• This represents a 254% premium to the closing share price prior to the initial acquisition proposal on September 12, 2024.
• The Board of Directors formed a special committee to evaluate strategic alternatives and negotiate the merger agreement.
• The transaction is subject to customary conditions, including stockholder approval, and is expected to close in the first half of 2025.
• Upon completion, Singular Genomics will become a private company.
• TD Securities and Houlihan Lokey served as financial advisors to the Special Committee, while Gunderson Dettmer, LLP served as legal advisor to Singular Genomics.
• Katten Muchin Rosenman LLP is serving as legal advisor to Deerfield.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the high premium offered to shareholders and the expectation of greater flexibility as a private company. However, there are inherent risks associated with the transaction, preventing a higher score.

Positives

• The acquisition provides a significant premium to Singular Genomics' shareholders.
• Becoming a private company is expected to provide Singular Genomics with greater flexibility.
• Deerfield has expressed its support for Singular Genomics' business strategy and future endeavors.

Risks

• The transaction is subject to customary closing conditions, including stockholder approval.
• The transaction may not close in a timely manner or at all.
• There is a risk of competing offers or acquisition proposals.
• The pendency of the transaction could affect Singular Genomics' ability to retain key personnel and maintain relationships.
• There is a risk of stockholder litigation in connection with the proposed transaction.

Future Outlook

The transaction is expected to close in the first half of 2025, subject to customary closing conditions, including stockholder approval.

Management Comments

• Andrew ElBardissi, M.D., Partner at Deerfield, stated that they are proud to support Singular Genomics as they embark on this exciting new chapter, advancing science and serving their customers with excellence.

Industry Context

The acquisition reflects continued interest in the next-generation sequencing and multiomics technology space, with private equity firms seeking to capitalize on innovative platforms.

Comparison to Industry Standards

• Comparable companies in the genomics space include Illumina, Pacific Biosciences, and 10x Genomics.
• The acquisition multiple and premium offered can be compared to other recent transactions in the life science tools and diagnostics industry to assess its fairness.

Stakeholder Impact

• Shareholders will receive a significant premium for their shares.
• Employees may experience changes as the company transitions to private ownership.
• Customers and suppliers may see changes in the company's strategic direction.

Next Steps

• The Company will file a proxy statement with the SEC.
• The Company will hold a special meeting of stockholders to approve the merger agreement.
• The parties will work to satisfy customary closing conditions.

Key Dates

Keywords

merger, acquisition, Singular Genomics, Deerfield, NGS, multiomics, stockholders, agreement